Alnylam Pharmace. buy BMO Capital Markets
Start price
05.09.25
/
50%
€386.00
Target price
05.09.26
€402.93
Performance (%)
-30.57%
Price
17:54
€268.00
Summary
This prediction is currently active. The BUY prediction by BMO_Capital_Markets for Alnylam Pharmace. is performing very badly with a performance of -30.57%. This prediction currently runs until 05.09.26. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -2.939% | -2.939% |
| iShares Core DAX® | -1,50 % | 7,70 % |
| iShares Nasdaq 100 | 1,38 % | 16,28 % |
| iShares Nikkei 225® | -1,99 % | 13,11 % |
| iShares S&P 500 | 0,35 % | 10,82 % |
Comments by BMO_Capital_Markets for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) was given a new $470.00 price target on by analysts at BMO Capital Markets. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by BMO_Capital_Markets for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€210.70
24.06.24
24.06.24
€218.11
24.06.25
24.06.25
32.04%
25.06.25
25.06.25
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€141.40
27.03.24
27.03.24
€216.31
27.03.25
27.03.25
74.96%
28.03.25
28.03.25